Secukinumab in the treatment of psoriasis: patient selection and perspectives
Eric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract: Secukinumab is a human monoclonal antibody targeti...
Main Authors: | Yang EJ, Beck KM, Liao W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Psoriasis : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/secukinumab-in-the-treatment-of-psoriasis-patient-selection-and-perspe-peer-reviewed-article-PTT |
Similar Items
-
Secukinumab-induced Oral Lichen Planus: A Report of Case and Review of Literature
by: Munise Daye, et al.
Published: (2021-08-01) -
Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
by: Bruna Lavinas Sayed Picciani, et al.
Published: (2021-06-01) -
Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature
by: Nawaf Almutairi, et al.
Published: (2020-01-01) -
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
by: Silvia Vidal, et al.
Published: (2021-06-01) -
Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study
by: Ramesh M Bhat, et al.
Published: (2017-01-01)